Christine Brown, Ph.D.
- Heritage Provider Network Professor in Immunotherapy
- Associate Director, T Cell Therapeutics Research Laboratory
- Research Professor, Departments of Hematology & Hematopoietic Cell Transplantation and Immuno-Oncology
Christine Brown, Ph.D.
- Chimeric Antigen Receptor T cell therapy for cancer, with particular focus on its application to brain tumors
- Brain tumor immunology
- Glioma cancer stem cells
Dr. Christine Brown is a faculty member in the Departments of Hematology & Hematopoietic Cell Transplantation and Immuno-Oncology.
As Associate Director of the T Cell Therapeutics Research Laboratory (TCTRL), Dr. Brown provides scientific oversight for the pre-clinical research program, as well as the ongoing clinical trial program focused on the development of chimeric antigen receptor (CAR)-engineered T cells for the treatment of hematological malignancies and solid tumors. Dr. Brown’s personal research efforts are focused on developing and refining re-directed CAR T cells for the treatment of malignant brain tumors.
Dr. Brown received her doctoral degree from the University of California, Berkeley, and was a Leukemia & Lymphoma Scholar during her post-doctoral fellowship at Pennsylvania State University. Her scientific contributions to the development and optimization of tumor-specific CAR T cells for the treatment of glioblastoma are supported by the California Institute for Regenerative Medicine (CIRM) and are the basis of an on-going phase I clinical trial which is supported by Gateway for Cancer Research and R01 FD005129.
- 2016 - present, Heritage Provider Network Professor in Immunotherapy, City of Hope, Duarte, CA
- 2013 - present, Associate Director, T Cell Therapeutics Research Laboratory, City of Hope, Duarte, CA
- 2015 - present, Research Professor, Departments of Hematology & Hematopoietic Cell Transplantation and Immuno-Oncology, City of Hope, Duarte, CA
- 2010 - 2015, Associate Research Professor, Departments of Hematology & Hematopoietic Cell Transplantation and Immuno-Oncology, City of Hope, Duarte, CA
- 2005 - 2013, Group Leader, T cell Therapy Preclinical Research, Department of Cancer Immunotherapeutics & Tumor Immunology, Beckman Research Institute of City of Hope, Duarte, CA
- 2002 - 2010, Assistant Research Professor, Department of Cancer Immunotherapeutics & Tumor Immunology, Beckman Research Institute of City of Hope, Duarte, CA
- Hematology & Hematopoietic Cell Transplantation
- Neuro-Oncology Disease Team
- Cancer Center Program Member, Cancer Immunotherapeutics Program
- 1992 - 1998, Ph.D., Department of Cell and Molecular Biology, University of California, Berkeley, Berkeley, CA
- 1985 - 1990, Bachelor of Science, Combined Science - emphasis Biochemistry, minor Chemistry, Santa Clara University, Santa Clara, CA
- 1998 - 2001, Department of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, PA
My research is focused on the development of chimeric antigen receptor (CAR) T cell therapy for the treatment of cancer. I conceptualize, perform and oversee studies to evaluate CAR design, T cell manufacturing, cell-based immunological assays and in vivo animal models. My primary independent research efforts are focused on the development of CAR T cell therapy for the treatment of primary and metastatic brain tumors.
As Associate Director of the T cell Therapeutics Research Laboratory (TCTRL), I also lead multi-functional teams to translate these therapies to the clinical, participating in all stages of the regulatory process.
January 30, 2018
January 26, 2018
July 17, 2017
July 10, 2017
February 03, 2017
October 17, 2016
September 27, 2016
October 26, 2015
February 16, 2015
January 27, 2015
February 03, 2014
Information listed here is obtained from Pubmed, a public database; City of Hope is not responsible for its accuracy. View all publications.
- Cui Q, Yang S, Ye P, Tian E, Sun G, et al. Downregulation of TLX induces TET3 expression and inhibits glioblastoma stem cell self-renewal and tumorigenesis. Nature communications. 2016; 7:10637. PubMed [journal] PMID: 26838672, PMCID:PMC4742843
- Hong H, Brown CE, Ostberg JR, Priceman SJ, Chang WC, et al. L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice. PloS one. 2016; 11(1):e0146885. PubMed [journal] PMID: 26761817, PMCID: PMC4711972
- Priceman SJ, Forman SJ, Brown CE. Smart CARs engineered for cancer immunotherapy. Current opinion in oncology. 2015; 27(6):466-74. NIHMSID: NIHMS733405 PubMed [journal] PMID: 26352543, PMCID: PMC4659816
- Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, et al. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015; 21(18):4062-72. NIHMSID: NIHMS699687 PubMed [journal] PMID: 26059190, PMCID: PMC4632968
- Wang X, Wong CW, Urak R, Mardiros A, Budde LE, et al. CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015; 21(13):2993-3002. NIHMSID: NIHMS677258 PubMed [journal] PMID: 25838392, PMCID: PMC4489991
- Jonnalagadda M, Mardiros A, Urak R, Wang X, Hoffman LJ, et al. Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Molecular therapy : the journal of the American Society of Gene Therapy. 2015; 23(4):757-68. PubMed [journal] PMID: 25366031, PMCID: PMC4395772
- Wen W, Liang W, Wu J, Kowolik CM, Buettner R, et al. Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer. Molecular cancer therapeutics. 2014; 13(12):3037-48. NIHMSID: NIHMS634418 PubMed [journal] PMID: 25319391, PMCID: PMC4321961
- Thaci B, Brown CE, Binello E, Werbaneth K, Sampath P, et al. Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. Neuro-oncology. 2014; 16(10):1304-12. PubMed [journal] PMID: 24723564, PMCID: PMC4165413
- Herrmann A, Cherryholmes G, Schroeder A, Phallen J, Alizadeh D, et al. TLR9 is critical for glioma stem cell maintenance and targeting. Cancer research. 2014; 74(18):5218-28. NIHMSID: NIHMS614918 PubMed [journal] PMID: 25047528, PMCID: PMC4167470
- Hong H, Stastny M, Brown C, Chang WC, Ostberg JR, et al. Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes. Journal of immunotherapy (Hagerstown, Md. : 1997). 2014; 37(2):93-104. PubMed [journal] PMID: 24509172
- American Association for Cancer Research
- American Society of Gene and Cell Therapy
- Society of Immunotherapy of Cancer
- Society of Neuro-Oncology
- Caltech/UCLA/CHLA/COH Engineered Immunity Consortium
- 1998, Postdoctoral Fellowship, Howard Hughes Medical Institute
- 2000, Scholar, Leukemia and Lymphoma Society
- 2012, Values in Action Award for Intellectual Curiosity, City of Hope
- 2013, Developmental Research Award Recipient, Lymphoma SPORE